• Improved Patient Safety.
• Streamlined Regulatory Compliance
• Enhanced Supply Chain Management
• Facilitated Post-market Surveillance

Global Implementation of UDI

The adoption of UDI is becoming increasingly important on a global scale. Various countries are in different stages of implementing UDI regulations, aligning with local requirements and international standards such as those set by the International Medical Device Regulators Forum (IMDRF). Below is a summary of countries that have implemented or are in the process of implementing UDI

1. Accessibility: eIFUs can be accessed from anywhere with an internet connection, making them more accessible than paper-based instructions.

2. Timeliness: eIFUs can be updated more easily and quickly than paper-based instructions, ensuring that users always have access to the most up-to-date information.

3. Cost Savings: eIFUs can help reduce costs associated with printing, shipping, and distributing paper-based instructions.

4. Environmental Benefits: eIFUs can reduce paper waste and the environmental impact associated with the production and disposal of paper-based instructions.

5. User-friendliness: eIFUs can include interactive features such as videos, animations, and hyperlinks, which can make them more user-friendly and easier to understand than traditional paper-based instructions.

Overall, eIFUs offer a more convenient, efficient, and sustainable way to provide instructions for use of medical devices, while also improving accessibility and user experience.

Want to stay ahead of the curve with eIFU labeling for medical devices? Learn about the benefits and regulations here.

The below information is provided based on the information available to the Commission services following a consultation of the Medical Device Coordination Group (MDCG) in October 2023.

Purpose of Vigilance System

Principal purpose of the Medical Device Vigilance System is to improve the protection of health and safety of patients, USERs and others by reducing the likelihood of reoccurrence of the INCIDENT elsewhere. This is to be achieved by the evaluation of reported INCIDENTs and, where appropriate, dissemination of information, which could be used to prevent such repetitions, or to alleviate the consequences of such INCIDENTs.

Medical Device Vigilance System includes:

1. Manufacturers

2. National Competent Authorities (NCA)

3. The European Commission

4. Notified Bodies

5. USERs and others concerned with the continuing safety of MEDICAL DEVICEs

What are Vigilance requirements?

Vigilance requirements includes Incident Reporting System using PSUR’s, FSCA’s, FSN’s, MIR’s, Trend Reports and PSR’s.

Definitions:

Periodic Safety Update Report (PSUR): The main objective of a PSUR is to present a summary of the results and conclusions of the analyses of post-market surveillance data relating to a device or a device group, thus allowing the reporting of any possible changes to the benefit-risk profile of the medical device(s), considering new or emerging information in the context of cumulative information on benefits and risks.

Field Safety Corrective Action (FSCA): A ‘Field Safety Corrective Action (FSCA)’ is a corrective action taken by a manufacturer for technical or medical reasons to either prevent or reduce the risk of a serious incident, which is associated with a device that is made available on the market.

Field Safety Notice (FSN): A ‘Field Safety Notice (FSN)’ is a communication sent by a manufacturer to users or customers in relation to a field safety corrective action.

Trend Report: Any statistically significant increase in the frequency or severity of incidents that are not serious incidents or that are expected undesirable side-effects that could have a significant impact on the benefit-risk analysis and which have led or may lead to risks to the health or safety of patients, users or other persons that are unacceptable when weighed against the intended benefits. The significant increase shall be established in comparison to the foreseeable frequency or severity of such incidents in respect of the device, or category or group of devices, in question during a specific period as specified in the technical documentation and product information.

Periodic Summary Report (PSR): A ‘Periodic summary report’ (PSR) is an alternative reporting regime by which the manufacturer, in agreement with the respective national competent authority that is coordinating the periodic summary reporting (and in consultation with the competent authorities referred to in Article 92(8) (a) MDR), can report similar serious incidents with the same device or device type in a consolidated way. Criteria for periodic summary reporting include situations where; the root cause has been identified, a FSCA has been implemented or where the serious incidents are common and well documented.

Submission of Vigilance Requirements in EUDAMED:

PSUR

Step 1: Preparation of PSUR

The PSUR preparation and issuance timeline refers to the period required for the manufacturer to prepare and submit PSUR (for Class III, Class IIa and Class IIb implantable devices according to Article 86) to the Notified Body via EUDAMED or make it available to the Notified Body after the end of the data collection period.

Step 2: Registering a PSUR in EUDAMED using PSUR Web Form for Manufacturer

The PSUR Web form for manufacturer contains all the relevant administrative data necessary for the registration of the PSUR in EUDAMED: certain fields are automatically populated by EUDAMED e.g. Notified Body, Manufacturer, Single Registration Number (SRN) while other data need to be filled up by the manufacturer via EUDAMED Web interface

The manufacturer should create a PSUR reference number which should remain the same for the PSUR updates. In case of grouping of devices within one PSUR, the PSUR reference number relates to the leading device.

When registering a PSUR in EUDAMED, the manufacturer should capture the Basic UDI-DIs of all the Class III or implantable devices belonging to the group via the web interface.

Step 3: Submission of PSUR

Depending on the class of the device and in accordance with Article 86(2), the manufacturer should either submit the PSUR to the Notified Body via EUDAMED or make it available to the Notified Body involved in the conformity assessment.

When EUDAMED becomes fully functional, the manufacturer should upload the PSUR in PDF format into EUDAMED for MDR class III devices or implantable devices and provide the information* of the PSUR Web form directly through the EUDAMED Web interface.

FSCA, FSN, MIR, PSR:

Step 1: Reporting of Serious Incidents and Field Safety Corrective Actions

Manufacturers of devices made available on the Union market, other than investigational devices, shall report, to the relevant competent authorities, in accordance with Articles 92(5) and (7), the following:

a) Any serious incident involving devices made available on the Union market, except expected side-effects which are clearly documented in the product
information and quantified in the technical documentation and are subject to trend reporting pursuant to Article 88;

b) Any field safety corrective action in respect of devices made available on the Union market, including any field safety corrective action undertaken in a third country in relation to a device which is also legally made available on the Union market, if the reason for the field safety corrective action is not limited to the device made available  in the third country.

c) For similar serious incidents that occur with the same device or device type and for which the root cause has been identified or a field safety corrective action  implemented or where the incidents are common and well documented, the manufacturer may provide periodic summary reports instead of individual serious incident       reports, on condition that the coordinating competent authority

• Manufacturers should report serious incidents and field safety corrective actions to the respective/relevant national vigilance systems. The new MIR form has already been adapted to MDR requirements and should be used accordingly.
• The current FSCA form should be used (the additional information required under the MDR may be added to the general comments section of the form).

The reporting timelines outlined in the MDR are the following:

1. Any serious incident, that did not involve a death or an unanticipated serious deterioration in a person’s state of health, must be reported immediately after a causal relationship between device and the serious incident has been established or is reasonably possible and no later than 15 days after the awareness date of the serious incident (Article 87(3) MDR),

2. A serious public health threat must be reported immediately, and not later than 2 days after the manufacturer becomes aware of that threat (Article 87(4) MDR),

3. Death or an unanticipated serious deterioration in a person’s state of health must be reported immediately after a causal relationship between the device and the serious incident is established or as soon as such relationship is suspected, and no later than 10 days after the awareness date of the serious incident (Article 87(5) MDR).

Trend Reporting

Manufacturers shall report, by means of the electronic system referred to in Article 92, any statistically significant increase in the frequency or severity of incidents that are not serious incidents or that are expected undesirable side- effects that could have a significant impact on the benefit-risk analysis referred to in Sections 1 and 5 of Annex I and which have led or may lead to risks to the health or safety of patients, users or other persons that are unacceptable when weighed against the intended benefits.

Step 2: Analysis of Serious Incidents and Field Safety Corrective Actions

• Manufacturers should submit the final report to the respective / relevant national vigilance system.
• Communication with other competent authorities should take place through a dedicated secure directory in CircaBC (organised by the Commission) for MDR devices.
• For Legacy and older devices, the existing Eudamed2 system for NCAR should continue to apply
• Manufacturers should submit the field safety notices to the respective/relevant national vigilance systems.
• The respective/relevant competent authorities should make these field safety notices publicly available/accessible to the public in accordance with theirnational legislation.
• The coordinating competent authority shall inform by email or other suitable communication channels, the other competent authorities, the manufacturer and the Commission that it has assumed the role of coordinating competent authority

Step 3: Submission of FSCA, FSN, Trend Report, PSR and MIR

The use of the new MIR form has been mandatory since January 2020 and as a general rule, we advise sending both the PDF and XML to national Competent Authorities as not all Member States will adopt the new XML (XSD) schema.

FSCA, FSN, Trend Report, PSR can be send in both PDF and XML to national Competent Authorities as not all Member States will adopt the new XML (XSD) schema.

*The templates of FSCA, FSN, Trend Report and PSR reports are not updated as per MDR, the additional information required under the MDR may be added to the general comments section of the form.

For EUDAMED solutions like UDI, Vigilance, ViSU has modules for these to automate. Please reach out to us in case if you want to review or discuss these solutions

• Enabling quick identification of equipment affected by field safety corrective actions, failures, recalls, and major adverse events
• Using distribution records to support the identification of medical device
• Reducing medical errors
• Facilitating medical device data capture

Note:

• All class B, C or D medical devices including in vitro diagnostics (IVDs) are required to be registered with HSA on the SMDR (Singapore Medical Device Register) prior to their placement on the Singapore market.
• UDI implementation for all Class A General medical devices and IVDs may be done on a voluntary basis. The Class A medical devices are required to be listed on the Class A medical device database.
• UDIs will not be required for medical devices for clinical research, investigational testing or clinical trial and custom-made medical devices.
• Medical devices authorised for supply via Special Access Routes (GN26, GN27, GN29) are required to comply with UDI requirement on a risk-calibrated approach.

Unless otherwise stated, medical devices that are delivered in Singapore after the relevant compliance date based on the risk class are required to comply with the UDI requirement.

Transitional period to meet each implementation phase’s requirements

As of the relevant UDI compliance dates, all medical devices imported into Singapore must bear the UDI on the label. Companies will, however, have a further six months after the compliance date to deplete any medical devices that they may have imported before the compliance date and that are still in their current supply chain. For instance, starting on November 1, 2022, all medical equipment imported into Singapore must comply with the UDI requirements. Before 1 May 2023, all local inventories of these medical devices that were previously imported before 1 November 2022 should be delivered. All medical device dealers such as registrants, importers, wholesalers and manufacturers of phase 1 must be UDI compliant as of May 1, 2023.

Considerations for Singapore registrants already compliant to US, EU UDI rules

For medical devices marketed in the EU or the USA, UDIs used on the labels for those markets will be recognized as-is for a similar labeled use in Singapore.

Product owners should contact the issuing agency chosen by HSA Singapore, to activate UDI on any devices that are not sold in the EU or the USA.

How DDi will help

• DDi provides support in establishing a UDI strategy for the entire product line that complies with Singapore UDI requirements.
• DDi ensures 100% UDI approach for full suite of products and regulatory compliance.

Learn more about UDI strategy and ensuring regulatory compliance.